Title
Category
Credits
Event date
Cost
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Expert faculty for this 30-minute webinar will include a pathologist and a gynecologic oncologist. Faculty will summarize the latest guidelines on genes that should be tested in ovarian cancer and the appropriate identification of patients who should receive testing. The benefits and limitations of various testing technologies will be discussed (e.g., multigene panel testing), as well as the utility of measuring other indicators of genomic instability (e.g., HRD, LOH, etc.).
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Expert faculty for this 30-minute webinar will include a gynecologic oncologist and a nurse. This webinar will provide an overview of the latest data in PARP inhibitor therapy for the treatment of ovarian cancer in patients with different biomarker profiles and at different stages of the disease. Recent clinical data and rationale for PARP inhibitor use in the first-line maintenance setting will be discussed.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Expert faculty for this 30-minute webinar will include perspectives from a patient, a medical oncologist, and an oncology nurse. This webinar will focus on both modifiable and non-modifiable risk factors to both guideline-recommended genetic testing and access to appropriate treatment for testing. Strategies to increase patient shared decision-making, communication, and multidisciplinary collaboration will be explored.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
$0.00
This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
  • Hematology
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join key thought leaders in the world of bladder cancer – Drs. Sam Chang and Shilpa Gupta – as they review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy.
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
  • Oncology
  • ANCC
  • Participation
$0.00
Join our expert Nursing faculty as they review immune checkpoint inhibitor (ICI) data across bladder cancer treatment, from NMIBC to MIBC to locally advanced/metastatic disease. Our experts also will provide an understanding of effective therapeutic sequencing of platinum-based chemotherapy, ICIs, targeted therapies, and antibody-drug conjugates, as well as integration of novel combinatorial regimens in both first-line and later lines of therapy.
  • Oncology
  • ANCC
  • Participation
$0.00
Strategically designed to foster an understanding of both the disease state complexity and far-reaching disparity intrinsic to endometrial cancer, this educational session will begin with an appraisal of the utility and importance of biomarker testing in advanced endometrial cancer, and the latest data related to immune checkpoint inhibitor treatments in advanced endometrial cancer. The role of the oncology nurse in mitigating and managing toxicities with these agents will also be explored.
  • Hematology
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
$0.00
Listen on CEConversations

Pages